Navigation Links
Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 23, 2007 - Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported that its lead product, Defibrotide, will be the subject of a poster presentation at the World Congress of Nephrology 2007 being held in Rio de Janeiro, Brazil from April 21-25, 2007.

On Monday, April 23, 2007, Cinara Echart, Ph.D., Manager of Biological Research Laboratory at Gentium, will present a poster entitled "Defibrotide Modulates Glucose-Induced Heparanase Expression In Endothelial Cells: A Potential Mechanism Of Anti-Diabetic Activity" (Abstract #1382).

Diabetic nephropathy is characterized by a loss of glomerular basement membrane (GBM) integrity, which is a major cause of end-stage renal failure. Heparanase plays a key role in this aberrant remodeling of the GBM and has been shown to be up-regulated by hyperglycemic conditions such as found in diabetic patients.

Discussing the results, Dr. Echart said, "Our data suggests that Defibrotide not only has an effect on the down-regulation of heparanase gene expression, but also decreases its enzymatic activity in endothelial cells. Since heparanase is a critical factor in maintaining GBM integrity and is elevated in diabetic nephropathy, it should be considered for the management of this disease."

Laura Ferro, M.D., Gentium's president and chief executive officer, said, "These preclinical results are very exciting and encourage us to pursue further studies of Defibrotide's therapeutic potential in the management of diabetic nephropathy, a chronic disease for which there are limited treatment options. Further encouraging is that these data corroborate recently reported preclinical data showing Defibrotide to suppress heparanase expression and heparanase enzymatic activity in multiple myeloma cell lines."

It has previously been reported that Defibrotide, a polydisperse oligonucleotide with anti-thrombotic, thro mbolytic, anti-ischemic and anti-angiogenic proprieties, suppressed in vitro both the expression of heparanase gene and heparanase enzymatic activity in multiple myeloma tumor cell lines. Consequently, this study addressed Defibrotide's effectiveness to regulate the expression and activity of heparanase in human microvascular endothelial cell (HMEC) and rat kidney epithelial cell lines (NRK52E) grown in hyperglycemia conditions.

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, discovery and development of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status and Fast Track Designation by the U.S. Food and Drug Administration to treat Severe Veno-occlusive disease (VOD) and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F for the year ended December 31, 2005 under the caption "Risk Factors."

Source: Gentium


Gentium, S.p.A.
Gary G. Gemignani, Chief Financial Officer
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777
Bruce Voss, 310-691-7100
Luca Ricci Maccarini, +39 02.721431


Related medicine technology :

1. Gentiums Defibrotide Seen as Active in Multiple Myeloma
2. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  BioPlast Manufacturing, ... the medical research, clinical diagnostic and biotech environments, ... leading manufacturer of quality petri dishes. This acquisition ... clients a platform of products that are designed ... with the highest quality.  ...
(Date:11/24/2015)... brand Revo has debuted a new capsule collection ... Bono as part of the " Buy Vision, Give Sight ... than 5 million people by 2020.  --> ... sale of every pair of Revo sunglasses, including Bono,s "Vision ... to the "Buy Vision, Give Sight" initiative. These funds will ...
(Date:11/24/2015)... USA , Inc. (OTCQB: WCUI), today provided an update ... to targeted dermatology markets in Boston , ... North Carolina . This follows earlier shipments to the ... , and New York dermatology markets. ... reported on October 1, 2015 will be realized in the pending quarter, ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the latest ... hit their goal of $20,000 in under 10 hours. , The campaign, ... PRO Weight Loss Vest to the market. , The PRO Vest provides consumers with a ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... Exercise and Healthy Aging Program have announced their endorsement of the ... “American Specialty Health Fitness is proud to have the MFN as one of ...
(Date:11/24/2015)... Geneva, IL (PRWEB) , ... November 24, 2015 , ... All her life, Don Peck’s ... Even her obituary said she might have been. After a 25-year search for ... Mayflower voyager with whom she shared a last name. Turns out, it was Don’s ...
(Date:11/24/2015)... ... ... “I am so thrilled, as a newbie here, to leave a mark for the entire ... Lounge Makeover® from California Casualty . Stephanie is in her fifth year teaching at ... tenure. , “This is such an amazing school and we deserve a space where we ...
Breaking Medicine News(10 mins):